With several RNAi-based drugs in the clinic, including one already in phase II trials, the number of companies working in the field continues to grow. One of the newest is Norway-based siRNAsense, which is focusing on cancer and says it could be ready for human trials of its own -possibly as early as 2008.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.